The Drucker laboratory is located in the Samuel Lunenfeld Research Institute (SLRI), Mount Sinai Hospital, in downtown Toronto immediately adjacent to the downtown University of Toronto campus.
The laboratory carries out studies on the control of glucagon gene expression, and on the physiology of the glucagon-like peptides and their receptors. An updated summary of recent Research from the Drucker Laboratory is maintained on an ongoing basis, as is a list of recent Drucker lab publications and Drucker Lab Reagents. The laboratory is comprised of research technicians, Graduate students from the Departments of Laboratory Medicine and Pathobiology and Institute of Medical Sciences, as well as Research fellows appointed to the Department of Medicine at the University of Toronto. Information for prospective students and research fellows at the University of Toronto may be found at the SGS Website.
Dr. Daniel J. Drucker is an Endocrinologist and Professor of Medicine in the Division of Endocrinology, Department of Medicine, University of Toronto. Dr. Drucker received training in Internal Medicine and Endocrinology from the Johns Hopkins Hospital in Baltimore and the Toronto General Hospital, University of Toronto and completed a research fellowship in Molecular Endocrinology at the Massachusetts General Hospital. Dr. Drucker established his own laboratory research program in 1987 in Toronto. Dr. Drucker is currently Director of the Banting and Best Diabetes Centre at the University of Toronto.
Research in the Drucker lab is funded by grants from the Canadian Institutes of Health Research, the Juvenile Diabetes Foundation, and the Canadian Diabetes Association, and the National Cancer Institute. Funding for graduate Students and research fellows is available through these and other agencies National Cancer Institute, and through University Departmental funds at the University of Toronto. For additional information about research opportunities, contact Dr. D. Drucker. For specific information about the Banting and Best Diabetes Centre, contact Rose LaBarbera at diabetes.bbdc@utoronto.ca
Disclosure: Dr. Drucker maintains this Website and is responsible for Website content. Due to the increasing interest in the pharmaceutical potential of glucagon and the glucagon-like peptides, a number of these peptides and analogues and DPP-4 inhibitors are now approved drugs and/or in clinical development. Dr. Drucker has served as an advisor or consultant within the past 12 months to Amylin Pharmaceuticals, Arena Pharmaceuticals Inc., Arisaph Pharmaceuticals Inc., Eli Lilly Inc, Glaxo Smith Kline, Glenmark Pharmaceuticals, Hoffman LaRoche Inc, Isis Pharmaceuticals Inc., Merck Research Laboratories, Metabolex Inc., Novartis Pharmaceuticals, Novo Nordisk Inc., Phenomix Inc, and Transition Pharmaceuticals Inc. Neither Dr. Drucker or his family members hold stock directly or indirectly in any of these companies.